Home › Cancro ai polmoni › New York
Studi clinici su Cancro ai polmoni nello stato di New York
93 studi su Cancro ai polmoni cercano partecipanti presso sedi nello stato di New York.
Città nello stato di New York
- New York City60 studi
- Queens22 studi
- Greenburgh17 studi
- Buffalo16 studi
- Rochester15 studi
- The Bronx13 studi
- Staten Island12 studi
- New Rochelle11 studi
- Syracuse6 studi
- Queensbury5 studi
- Yonkers4 studi
- Brooklyn3 studi
- Rome3 studi
- Albany3 studi
Testo ufficiale dello studio (inglese)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Northwell Health Imbert Cancer Center, Bay Shore
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- e altri 18
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04991025The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute IDS, Buffalo
- Memorial Sloan Kettering Hospital, New York
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Glens Falls Hospital, Glens Falls
- Upstate Cancer Center at Oswego, Oswego
- University of Rochester, Rochester
- e altri 7
In reclutamentoFase 3
Età 70 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- The Cancer Institute at Saint Francis Hospital, East Hills
- e altri 13
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT04181060Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775Empathic Communication Skills (ECS) Training
- Roswell Park Cancer Institute (Data Collection Only), Buffalo
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
In reclutamentoVolontari sani benvenuti
Età da 18 a 100 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05456841Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Optum Medical Care, PC, Westbury
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06765109Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06881784Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- MSK Commack, Commack
- MSK Westchester, East White Plains
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City
- e altri 3
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07476287A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, East Syracuse
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07099898A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Cayuga Medical Center ( Site 0086), Ithaca
- University Hospital at Stony Brook ( Site 0054), Stony Brook
- White Plains Hospital ( Site 0091), White Plains
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- New York Oncology Hematology, Albany
- New York Oncology Hematology, Clifton Park
- Hematology Oncology Associates of Rockland, Nyack
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Hematology Oncology Associates of Rockland, Nyack
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06758401A Registry for People With Lung Cancer
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- e altri 1
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06424327A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- WMCHealth Advanced Physician Services, Hawthorne
- Local Institution - 0128, Rochester
- Local Institution - 0518, Schenectady
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Buffalo
In reclutamentoFase 2
Età da 18 a 95 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Nuvance Health, Poughkeepsie
- Suny-Stony Brook University Cancer Center, Stony Brook
- White Plains Hospital, White Plains
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
- e altri 1
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07100080A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- NYU Langone Health Perlmutter Cancer Center, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07349537Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06287775Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- SUNY Upstate Medical University, Syracuse
- Montefiore Einstein Cancer Center, The Bronx
- Clinical Research Alliance, Westbury
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Maimonides Cancer Center, Brooklyn
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06561685A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- NYU Langone Health - Long Island, Mineola
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, New York
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06343402Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07185997Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
- White Plains Hospital, White Plains
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT06712355Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06582017Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT07718672Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer
- Roswell Park Cancer Institute, Buffalo
In reclutamento
Età 21 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05787834GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07017829Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.